Skip to content
Search

Latest Stories

7 million people lose access to local pharmacy since 2017

England lost around seven million hours of pharmacy care and time in the last two years
Rural areas were particularly impacted by pharmacy closures (gettyimages)

England lost around seven million hours of pharmacy care and time in the last two years, with rural areas particularly impacted

The National Pharmacy Association (NPA) has revealed shocking figures showing that millions of patients across England have lost access to pharmacies due to widespread closures and reduced operating hours.

According to NPA analysis of NHS data, around 1,250 pharmacies have permanently closed since 2017, and the majority of these closures have come in the last three years.


Given that each pharmacy serves an average of 5,600 people, this decline in pharmacy numbers means that about 7 million people—equivalent to one in eight of England’s population—have seen their local pharmacy shut down since 2017.

Furthermore, NPA analysis found that pharmacies in England were open for 551,000 hours a week in 2024, down from 620,000 at the same time in 2022, a reduction of around 7 million hours in the last two years.

Rural areas were particularly impacted, with Cambridgeshire, Wiltshire, Kent and Devon losing maximum hours of pharmacy care and time.

Kent saw 109,000 hours of pharmacy time lost in the last two years, Wiltshire lost 41,000 hours, Cambridgeshire 46,000 and Devon 49,000 hours.

NPA chair Nick Kaye expressed concern over the continuing loss of pharmacy services in rural areas, stating that it will “force vulnerable isolated patients to travel further for the care they need.”

He emphasised: "When pharmacies close, it means people have to travel further for care and the pharmacies that remain have to work harder to meet demand.

“When they are forced to cut hours to make ends meet it means people don’t have such flexibility to get advice or pick up medicines.”

The NPA highlighted that pharmacies have been forced to cut their opening hours or close altogether in recent years due to the impact of 40 per cent cuts to funding in the past decade.

The association has urged the government to take urgent action to reverse cuts to pharmacy budgets, warning that failure to do so could leave patients without vital medication and care.

Kaye said: “We’re relieved to hear that talks have finally begun for the long overdue pharmacy settlement but unless urgent and sustained increases in pharmacy funding are delivered imminently, this situation will only worsen and patients will face more and more difficulties getting the care they need and pharmacies will have no choice but to cut their services further to make ends meet.”

The NPA reiterated that if a new funding settlement fails to meet its five tests, they may recommend collective action—including cutting opening hours to contractual minimums.\

Pharmacy closures 

Recent data from the NHS Business Services Authority (NHS BSA) reveals that as of January 2025, England had 10,025 community pharmacies (excluding distance-selling pharmacies).

This marks a loss of 812 pharmacies since the start of 2021, when the total stood at 10,837.

There were 248 closures in 2024, averaging nearly five per week throughout the year.

Including distance selling pharmacies, the total number of pharmacies in England was recorded at 10,436.

Of the total, small independents (owning between 1-5 pharmacies) account for 4,900 pharmacies, holding the largest market share at 49 per cent.

Medium-sized groups (owning 6-99 pharmacies) account for 1,823 pharmacies, representing 18 per cent of the market share, while large pharmacy groups (owning 100+ pharmacies) now have 3,302 pharmacies, making up 33 per cent of the market share.

NHS funding contract ‘outdated and broken’

The Company Chemists’ Association (CCA) also voiced concern, attributing pharmacy closures and reduced hours to underfunding

“Patients have lost access to almost 3.4 million hours of pharmacy care a year since September 2022,” said CCA chief executive Malcolm Harrison.

He noted that over a third of these lost hours resulted from pharmacies being forced to cut their opening times due to the continued strain of historic underfunding.

The impact extends beyond the permanent closure of pharmacies as “ultimately it is patients and taxpayers who suffer from this reduction in access to NHS care,” Harrison said.

While community pharmacies want to deliver more care for patients, Harrison emphasised that they are held back by an “outdated and broken” NHS funding contract.

“After a decade without any funding increase, pharmacies desperately need additional money just to survive, and further long-term investment if they are do more,” he added.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less